PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Price Stock Quantity  
USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PD184352 (CI-1040) Chemical Structure

PD184352 (CI-1040) Chemical Structure
Molecular Weight: 478.67

Validation & Quality Control

Cited by 42 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PD184352 (CI-1040) is available in the following compound libraries:

MEK Inhibitors with Unique Features

Product Information

  • Compare MEK Inhibitors
    Compare MEK Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Targets MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
IC50 17 nM 17 nM
In vitro CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H9MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLQTWM2OD1yLkCyNlc3KM7:TR?=NV7kcWo5W0GQR1XS
CHP-212M2izTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TY[2lEPTB;MD6wNlg5PSEQvF2=MX\TRW5ITVJ?
EoL-1-cellNXfqcpQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HBdWlEPTB;MD6wOFE2OiEQvF2=NYL5W3dNW0GQR1XS
DU-4475NFzQeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGD2fmJKSzVyPUCuNFc2QTlizszNM3X0WXNCVkeHUh?=
MMAC-SFM{joOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnmTFhKUUN3ME2wMlExQTd2IN88US=>MonkV2FPT0WU
AGSMnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mme5TWM2OD1yLkGxO|E{KM7:TR?=MWTTRW5ITVJ?
M14M{LsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInuNlNKSzVyPUCuNVU1PjhizszNMU\TRW5ITVJ?
CP50-MEL-BMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NICxXGlKSzVyPUCuNVczPTRizszNMY\TRW5ITVJ?
C32MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrOZlF5UUN3ME2wMlE6ODd{IN88US=>M1jGWXNCVkeHUh?=
KMOE-2NF7KTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYe2XIN3UUN3ME2wMlE6Pzl3IN88US=>MWLTRW5ITVJ?
A101DM1[2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoX1TWM2OD1yLkKxOEDPxE1?MUDTRW5ITVJ?
KM12MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHMTWM2OD1yLkK0NFU4KM7:TR?=MkjmV2FPT0WU
HSC-4NWH2cHZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\STWM2OD1yLkK0N|k2KM7:TR?=NF3zfVhUSU6JRWK=
NOMO-1NEjvVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\rcmlEPTB;MD6yOVc1OiEQvF2=M1\nUnNCVkeHUh?=
MZ7-melMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjsbIZKSzVyPUCuNlY{PCEQvF2=NGLuZVNUSU6JRWK=
ACNNF34fGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnWboVKSzVyPUCuNlY4OzdizszNNEP5RndUSU6JRWK=
MEL-HOMljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTBwMke2OVIh|ryPMUPTRW5ITVJ?
BHT-101Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXhb4M{UUN3ME2wMlI5PjB4IN88US=>M4L2ZnNCVkeHUh?=
SK-MEL-28NXjPO|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrLTWM2OD1yLkOwOFA6KM7:TR?=NITpd4NUSU6JRWK=
KG-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTT[5dpUUN3ME2wMlMxPjZ6IN88US=>M4\mSHNCVkeHUh?=
COLO-679NVTa[JJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTBwM{K3NkDPxE1?Mn;QV2FPT0WU
SK-MEL-24NF3yfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnXTFVnUUN3ME2wMlMzQDF|IN88US=>MXXTRW5ITVJ?
G-361MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\oTWM2OD1yLkO2O|k2KM7:TR?=NXPwd3EyW0GQR1XS
KY821NFqwV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3e5dmlEPTB;MD6zO|kyKM7:TR?=MonVV2FPT0WU
KASUMI-1NI\DV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2H4VWlEPTB;MD6zPVkh|ryPNITIVoNUSU6JRWK=
HL-60M3fRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTBwNEGxNFch|ryPM2H3PXNCVkeHUh?=
K5MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPt[VhKSzVyPUCuOFMyOTdizszNMWTTRW5ITVJ?
KU812MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnN[mRKSzVyPUCuOFUzQTlizszNMnHQV2FPT0WU
SH-4NVLzR5dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHrdmt3UUN3ME2wMlQ3OjV4IN88US=>MkjTV2FPT0WU
HTC-C3MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXOSW5jUUN3ME2wMlQ3PTNzIN88US=>NGDWbW9USU6JRWK=
CP66-MELMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTScplKSzVyPUCuOFg5ODlizszNNEnmOo5USU6JRWK=
WM-115NWDKNVlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjwTWM2OD1yLkS5NlU4KM7:TR?=NET5SmhUSU6JRWK=
A2780M{H3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vic2lEPTB;MD60PVgzOyEQvF2=MV3TRW5ITVJ?
P12-ICHIKAWANWXlcJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fFT2lEPTB;MD62NVIzOSEQvF2=NUfRToxwW0GQR1XS
HMV-IINWj4[ZI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\KV2lEPTB;MD62OFQ3PSEQvF2=NUmyRm1[W0GQR1XS
HT-144M1S1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjjbpNKUUN3ME2wMlY1PjV5IN88US=>MlXDV2FPT0WU
LB2518-MELNWPWcWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T5O2lEPTB;MD63NVY{OiEQvF2=MWrTRW5ITVJ?
NCI-SNU-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;BUnNSUUN3ME2wMlc2PDN|IN88US=>NVn1eHU5W0GQR1XS
C2BBe1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjUTWM2OD1yLkixNFI{KM7:TR?=MXrTRW5ITVJ?
PSN1NHnDS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXZNGFKSzVyPUCuPVYyQTZizszNMk\SV2FPT0WU
UACC-257MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkizTWM2OD1yLkm2OFc{KM7:TR?=NVPHdIk6W0GQR1XS
RVH-421NWrYOG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\wTWM2OD1yLkm3NVgh|ryPMWfTRW5ITVJ?
GP5dMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LZOmlEPTB;MD65PFMxQCEQvF2=NHLNdWFUSU6JRWK=
TYK-nuNG\OT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTFwMEOxO|Ih|ryPNHLpc5hUSU6JRWK=
SK-N-ASMlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXX4cY1WUUN3ME2xMlA4QTR5IN88US=>MmnMV2FPT0WU
SW620NYL0[JZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Lpe2lEPTB;MT6xN|U{PCEQvF2=M{HjOHNCVkeHUh?=
HuP-T4NV\GToVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTFwMUizOVkh|ryPNGm5XXpUSU6JRWK=
A549NHPRbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmP0TWM2OD1zLkG5OVc3KM7:TR?=MUTTRW5ITVJ?
MewoNWHTeYlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DudWlEPTB;MT6yNFI4PiEQvF2=Mm\xV2FPT0WU
ONS-76MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEL4OVNKSzVyPUGuNlIxPDlizszNMoXlV2FPT0WU
SK-MEL-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTFwMkO0NVkh|ryPNGTqbJhUSU6JRWK=
RCM-1NFTKbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLyfI1KSzVyPUGuNlQxPDdizszNMYHTRW5ITVJ?
H-EMC-SSMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfnTWM2OD1zLkK5OlA5KM7:TR?=NFe0[ZJUSU6JRWK=
NCI-H2291M2HDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGixS2dKSzVyPUGuN|I2OzZizszNM3;5VXNCVkeHUh?=
SW1463NEPEVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTFwM{O3NlEh|ryPM3HEdnNCVkeHUh?=
LS-411NNH\ibVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTFwNEC1NVch|ryPM13zVXNCVkeHUh?=
BV-173NYPIcpl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofYTWM2OD1zLkS0NFE2KM7:TR?=NFjEfFlUSU6JRWK=
LS-513M1qwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1j1PGlEPTB;MT60OVE6OiEQvF2=MUTTRW5ITVJ?
LoVoMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NES2XHdKSzVyPUGuOFY{QTlizszNMn;4V2FPT0WU
HO-1-N-1NFO3RnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlSxTWM2OD1zLkWxOlM1KM7:TR?=NX\Zfm5IW0GQR1XS
ML-2NXLrS2ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvTTWM2OD1zLkWyPFY5KM7:TR?=NF\jdVVUSU6JRWK=
NCI-H1437NVHaTGxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHu2e49KSzVyPUGuOVUzPzVizszNNEn2cFNUSU6JRWK=
SW1116MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoH1TWM2OD1zLkW2N|k5KM7:TR?=NFzOcYZUSU6JRWK=
A4-FukNEfTS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3Hte2lEPTB;MT61O|A1PSEQvF2=M3jVU3NCVkeHUh?=
HD-MY-ZMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3HSlZ2UUN3ME2xMlU4Ozd4IN88US=>NEH2ZolUSU6JRWK=
SK-MEL-2MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\lfGlKSzVyPUGuOVc1PTlizszNNID6OFBUSU6JRWK=
RT-112NVn5R2FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fndWlEPTB;MT61PFk2OiEQvF2=MmXVV2FPT0WU
COLO-829NYrLVXZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXadlhKSzVyPUGuOlIzOzJizszNNIrMdYRUSU6JRWK=
OVCAR-5MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHaRlVKSzVyPUGuO|c3QDdizszNNYHOb4YzW0GQR1XS
NB69Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTFwN{i0Olkh|ryPNF\0flZUSU6JRWK=
NCI-H292M3HoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHVd41KSzVyPUGuPFY3QTlizszNMYTTRW5ITVJ?
LOXIMVIM1i2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TrOWlEPTB;MT64PVQzPyEQvF2=NX:4T4ZHW0GQR1XS
BPH-1MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LRS2lEPTB;MT64PVU6OSEQvF2=NITsUVFUSU6JRWK=
A375MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDuTWM2OD1zLki5O|E1KM7:TR?=NVrxd|JzW0GQR1XS
LCLC-97TM1NEHq[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTFwOUKyOVYh|ryPNY[zS5hWW0GQR1XS
RXF393Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fnOmlEPTB;MT65O|g5PyEQvF2=NEXWVXVUSU6JRWK=
HCC70NIjhSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoruTWM2OD1{LkCyOFI3KM7:TR?=NXexOpN4W0GQR1XS
EM-2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnL[WM5UUN3ME2yMlA4OTl6IN88US=>NUHrNZl7W0GQR1XS
MZ2-MELNI\zXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrHTWM2OD1{LkGxNVI4KM7:TR?=MX;TRW5ITVJ?
HNNYrUZYVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3WZoZ1UUN3ME2yMlE3Ojd6IN88US=>M1jiTHNCVkeHUh?=
A2058M{jxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zL[GlEPTB;Mj6xPVI4QSEQvF2=MoHOV2FPT0WU
NB7MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\BbGlEPTB;Mj6zOFA5PiEQvF2=MkPRV2FPT0WU
DOKMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJwM{W3O|Mh|ryPMYfTRW5ITVJ?
CAL-27MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfXdHFRUUN3ME2yMlM6OjN4IN88US=>MoXCV2FPT0WU
BB65-RCCM3;xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4Had2lEPTB;Mj60NFY4PCEQvF2=M2fBV3NCVkeHUh?=
RDMknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTucI45UUN3ME2yMlQ1PzJ|IN88US=>MlzWV2FPT0WU
KNS-62M4nmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorpTWM2OD1{LkWxNVY1KM7:TR?=MoX0V2FPT0WU
EW-13NHmz[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXTTWM2OD1{LkW2N|M6KM7:TR?=M2PE[HNCVkeHUh?=
DBNX3KdWEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fkUmlEPTB;Mj61PFc5QCEQvF2=NIDCOolUSU6JRWK=
HCC2218NYHJVHVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3zTWM2OD1{Lk[0O|c5KM7:TR?=NGq0OGFUSU6JRWK=
L-363MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3v6b2lEPTB;Mj63OFM4KM7:TR?=MoW1V2FPT0WU
CHL-1M3;VbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGD0Uo5KSzVyPUKuPFA4QDVizszNNH7zTGhUSU6JRWK=
BFTC-905MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETIcHBKSzVyPUKuPFI2OyEQvF2=NEnqO2ZUSU6JRWK=
HCE-TNYXMNVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDzTWM2OD1{LkizNlY1KM7:TR?=MVvTRW5ITVJ?
COLO-792MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVr1cJpxUUN3ME2yMlg1ODJ5IN88US=>MVfTRW5ITVJ?
LB2241-RCCMm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Dr[mlEPTB;Mj64OVg6OyEQvF2=M1jieXNCVkeHUh?=
CAL-39NVG5SphuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnv4TWM2OD1{Lki5PVk6KM7:TR?=M1WxdnNCVkeHUh?=
T-24M{jZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TlNGlEPTB;Mj65NVEyOiEQvF2=NFq3fHVUSU6JRWK=
NCI-H727M1rCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTJwOUG3PVYh|ryPNI\sbY5USU6JRWK=
Ca9-22NGKwNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnWxTWM2OD1{Lkm3NlU2KM7:TR?=MWDTRW5ITVJ?
MIA-PaCa-2MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;JcI5KSzVyPUOuNFA4QDFizszNMkOyV2FPT0WU
HT-1080NG\lWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLGNI5KSzVyPUOuNFE6QTdizszNNYjFOYJFW0GQR1XS
D-423MGM2P3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFX5bGlKSzVyPUOuNFc4PTNizszNNYX5[mFNW0GQR1XS
LAMA-84M3qzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGT2NmJKSzVyPUOuNVM2QCEQvF2=M{L0NHNCVkeHUh?=
SW780NY\POHI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3YV|ZEUUN3ME2zMlE1OjJ7IN88US=>MkLyV2FPT0WU
KU-19-19MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\NZnZTUUN3ME2zMlE4ODN2IN88US=>MkHqV2FPT0WU
COLO-741M4fGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTNwMUi2O|Mh|ryPMn7xV2FPT0WU
HSC-3NVjMXnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vG[2lEPTB;Mz6yN|E2OSEQvF2=NXyxZ5JXW0GQR1XS
SN12CNWHoU3ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NESyUZlKSzVyPUOuNlQ4ODFizszNMkKyV2FPT0WU
786-0M4TXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTNwMkeyOFMh|ryPNXPHSVk6W0GQR1XS
GAKMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[1OI9KSzVyPUOuN|I2PjFizszNNH:3eJZUSU6JRWK=
PANC-03-27M4LVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fhcGlEPTB;Mz6zOVA1PSEQvF2=NWOz[Zp3W0GQR1XS
CTB-1NUTjcIkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnmTWM2OD1|LkS3NFQ4KM7:TR?=MWLTRW5ITVJ?
A427M3zjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTNwNUm1OVYh|ryPMYnTRW5ITVJ?
EGI-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnBTWM2OD1|Lk[wOVg{KM7:TR?=NU\MSW9CW0GQR1XS
U-2-OSNHXCdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[4fWlEPTB;Mz62O|I2PiEQvF2=NYLXTmU4W0GQR1XS
NCI-SNU-5MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFyxUIZKSzVyPUOuOlc4OyEQvF2=NFzSToRUSU6JRWK=
SK-LU-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLVTWM2OD1|Lk[4O|k5KM7:TR?=MX;TRW5ITVJ?
697MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvOfGNKSzVyPUOuOlk3ODNizszNM4XVeXNCVkeHUh?=
HPAF-IIMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXCVXRwUUN3ME2zMlc2PDlizszNMlnvV2FPT0WU
NCI-H2087M{\1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXjVY9KSzVyPUOuPFQ3PzJizszNM13Ib3NCVkeHUh?=
SK-MEL-3MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3S[FhKSzVyPUOuPFUyPTRizszNM{ftcHNCVkeHUh?=
CGTH-W-1NHW0ZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXmS4xKSzVyPUOuPFU4OjVizszNNX\HbIJKW0GQR1XS
8505CM4K4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TmOWlEPTB;Mz65NFA4QCEQvF2=NWrVR|VLW0GQR1XS
GAMGNWLoOXk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTRwMEKzO|ch|ryPM4nRR3NCVkeHUh?=
SW626MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HpTGlEPTB;ND6wOFQ5KM7:TR?=NHmxV5dUSU6JRWK=
CAL-62NIDHSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIm0OJpKSzVyPUSuNFc1OyEQvF2=NXnBTopCW0GQR1XS
MHH-PREB-1NELxbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHH3U|FKSzVyPUSuNVIyOTFizszNMVHTRW5ITVJ?
RPMI-7951NXHQ[mFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTRwMkW1PFkh|ryPNEjTe|lUSU6JRWK=
HOP-92M4S0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2qzRmlEPTB;ND6yOVY4KM7:TR?=NF7VdFlUSU6JRWK=
MDA-MB-231NW\4dHVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUi0WVJQUUN3ME20MlI6OjJ|IN88US=>NUDwZpJVW0GQR1XS
LAN-6NYXzUlNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTRwM{G2N|ch|ryPM{LiU3NCVkeHUh?=
ALL-PONH\ET5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7SSIJiUUN3ME20MlM3OTV4IN88US=>NV7CRY93W0GQR1XS
HHMnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTRwNEG1PVch|ryPMVnTRW5ITVJ?
IGROV-1NUjP[Y9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTRwNEWxO|Eh|ryPMYXTRW5ITVJ?
NCI-H358M2q3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\wUHhKUUN3ME20MlQ2Ozh3IN88US=>MkDTV2FPT0WU
NB5MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3S2d2lEPTB;ND62NFM3QSEQvF2=MmrZV2FPT0WU
NCI-H747MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvkTJBKSzVyPUSuOlg5ODdizszNMXTTRW5ITVJ?
NH-12MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonLTWM2OD12LkexOlI2KM7:TR?=MlTrV2FPT0WU
LB1047-RCCM1WwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXOe2FKSzVyPUSuO|M5OTVizszNM{LUXnNCVkeHUh?=
EFO-27NXvTXW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHr6doVKSzVyPUSuO|g3PjdizszNMl62V2FPT0WU
EPLC-272HMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3raOWlEPTB;ND65PVY3QSEQvF2=NYqyfnRpW0GQR1XS
CAL-54MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjRfGlKSzVyPUWuNFI3QTVizszNM33Fc3NCVkeHUh?=
H4MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHYTWM2OD13LkC0NlU2KM7:TR?=NY\PRWs3W0GQR1XS
MOLT-13MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\STWM2OD13LkC2O|c3KM7:TR?=Mn7OV2FPT0WU
CAL-33NU\3UHJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;HR3I4UUN3ME21MlEzOzF5IN88US=>M1[0fXNCVkeHUh?=
23132-87NGPQNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFGwdmRKSzVyPUWuNVY5PzJizszNMUnTRW5ITVJ?
UM-UC-3M3T4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jpUmlEPTB;NT6xPFA1PyEQvF2=MYfTRW5ITVJ?
HuH-7NUe4TolvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjjW3pKUUN3ME21MlI4OTR5IN88US=>Ml;6V2FPT0WU
BCPAPMo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nRVWlEPTB;NT6zNlk3QSEQvF2=M4naVHNCVkeHUh?=
AsPC-1Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHkVYlkUUN3ME21MlM3PzZ|IN88US=>MY\TRW5ITVJ?
NCI-H1155NUTjcIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{G0T2lEPTB;NT60NFA2OSEQvF2=NEf6bpNUSU6JRWK=
GT3TKBNGDu[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTVwNE[1PVgh|ryPNH21d49USU6JRWK=
HCC2998MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljuTWM2OD13LkS5NVA6KM7:TR?=MnLiV2FPT0WU
NUGC-3MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7oWXFNUUN3ME21MlQ6OzB{IN88US=>Mlr2V2FPT0WU
Hs-578-TNWfifFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTVwNUO3PVQh|ryPNG[wU4ZUSU6JRWK=
FADUM1:3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTVwNUW3NlYh|ryPNFrmXFBUSU6JRWK=
NBsusSRNUDoN4xHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjrNFMzUUN3ME21MlU4OTV3IN88US=>M17rOXNCVkeHUh?=
ME-180M1;qRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFezRZJKSzVyPUWuOVgxQTJizszNMkewV2FPT0WU
SW1710NEKxPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3tTIRKSzVyPUWuOlE3PTRizszNM3XBXnNCVkeHUh?=
HuP-T3MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XLXWlEPTB;NT62NlAzQSEQvF2=MW\TRW5ITVJ?
HOSNGLWd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDCTWM2OD13Lk[yPVI{KM7:TR?=Mo\1V2FPT0WU
PA-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLmTWM2OD13Lk[0NlY2KM7:TR?=M17KXHNCVkeHUh?=
LU-99ANEXHZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nTfWlEPTB;NT62OlQ2OSEQvF2=MoLCV2FPT0WU
RS4-11NEnTc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonFTWM2OD13Lk[2O|c2KM7:TR?=MXnTRW5ITVJ?
TE-8M3njPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7DSJRJUUN3ME21MlY5PTN5IN88US=>NVX3bZhVW0GQR1XS
RERF-LC-MSMor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHkTWM2OD13Lk[4PFA{KM7:TR?=MnXxV2FPT0WU
MEL-JUSONVzGdWRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHOy[|dKSzVyPUWuO|M4QCEQvF2=MUDTRW5ITVJ?
SK-MES-1NFvqUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7WTWM2OD13LkizOVI5KM7:TR?=MnP1V2FPT0WU
D-263MGMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3i1W2lEPTB;NT64PFM2OSEQvF2=NHHSdnRUSU6JRWK=
NB10M1nZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LidmlEPTB;NT64PVQ3KM7:TR?=MmjmV2FPT0WU
SK-HEP-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonoTWM2OD13LkmzOFcyKM7:TR?=Mm\vV2FPT0WU
HT-29MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTVwOUixNVgh|ryPM3Xi[nNCVkeHUh?=
KYSE-140M1OzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjy[GFqUUN3ME22MlAzOTh{IN88US=>NH;yOHBUSU6JRWK=
NCI-H1666NHLDVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PXSGlEPTB;Nj6wPFQ3OSEQvF2=M4HwfHNCVkeHUh?=
NCI-H1304MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYftPWhJUUN3ME22MlE6QTRizszNMly0V2FPT0WU
RPMI-8866NIrxXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTZwMkGzNVMh|ryPM1PkdXNCVkeHUh?=
MV-4-11NWqz[ohET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHq4[GlKSzVyPU[uNlMyQTlizszNM1q1SnNCVkeHUh?=
A431M1\PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYSxd|ExUUN3ME22MlI1Ojl4IN88US=>NGn4dohUSU6JRWK=
PANC-10-05MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDHWXlMUUN3ME22MlI5OzZ|IN88US=>MlLUV2FPT0WU
TK10MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnJXHpFUUN3ME22MlMzPjB2IN88US=>NYL4ZYFiW0GQR1XS
NCI-H1975M4\zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjWOZJKSzVyPU[uOFczOTVizszNM2nxenNCVkeHUh?=
A172M2P3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvETWM2OD14LkS5NVc3KM7:TR?=Mk\mV2FPT0WU
D-566MGM1O5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPHTlN7UUN3ME22MlU1OzB|IN88US=>MknrV2FPT0WU
NCI-H2122M3vXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfaVWdnUUN3ME22MlYyPTJ6IN88US=>NX3Ve4hLW0GQR1XS
COR-L105MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTZwNkWyO|Uh|ryPM1jDZXNCVkeHUh?=
AN3-CANEnNU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTZwNki2OFEh|ryPMk\GV2FPT0WU
Calu-6NY[xeFdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1u2WWlEPTB;Nj63PVY6QCEQvF2=M4LrcXNCVkeHUh?=
HCT-116NX\uc|VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\hTWM2OD14LkixNlY1KM7:TR?=MX3TRW5ITVJ?
MHH-NB-11NGXXXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY[2dJp6UUN3ME22Mlg2ODB{IN88US=>MmLJV2FPT0WU
MFE-280M2DLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XtUWlEPTB;Nj64OVk5OyEQvF2=NIXQUodUSU6JRWK=
SW1088MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDZUJJKSzVyPU[uPVE6OTNizszNMnv3V2FPT0WU
SW48Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnSTWM2OD14Lkm0OVEh|ryPNEfqVZJUSU6JRWK=
HuCCT1NIrFNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknkTWM2OD15LkCxNFM4KM7:TR?=NHPjSVFUSU6JRWK=
ACHNMmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXpTWM2OD15LkCyPVQ{KM7:TR?=NXrkdXN2W0GQR1XS
8305CMkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3KTWM2OD15LkC5PVk2KM7:TR?=MmDSV2FPT0WU
DoTc2-4510NGHZPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLQXY5KSzVyPUeuNVIyPSEQvF2=MUjTRW5ITVJ?
COR-L23Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHFZlNqUUN3ME23MlI1PDJizszNM1r0VHNCVkeHUh?=
SK-MEL-30NGC1WVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXaTWM2OD15LkK1NFg{KM7:TR?=M1G4RnNCVkeHUh?=
BE-13MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\YeWlEPTB;Nz6zN|g{PCEQvF2=M3;MSXNCVkeHUh?=
GR-STM{K5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LxeWlEPTB;Nz60NFE4PCEQvF2=NFO2eGhUSU6JRWK=
LU-135NVnITZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnixTWM2OD15LkW1PVM6KM7:TR?=MkXzV2FPT0WU
U-266NV;NTWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHYTWM2OD15LkW2Nlg3KM7:TR?=MXTTRW5ITVJ?
NCI-H1355M3rNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3KWmZKSzVyPUeuOVg3OzVizszNM130T3NCVkeHUh?=
NB14MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLqVIFKUUN3ME23MlY3PjR{IN88US=>NFX1c3RUSU6JRWK=
SCC-25NG[xSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTdwN{C5JO69VQ>?NF3CbpJUSU6JRWK=
COLO-678NYqxbllVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3iS4Y{UUN3ME23MlcyODd4IN88US=>NGDST2VUSU6JRWK=
TGBC1TKBM4PvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTdwOEmzPVgh|ryPMoHDV2FPT0WU
IST-MEL1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;FeZIyUUN3ME24MlAxPDB4IN88US=>NWXkcoJ7W0GQR1XS
ECC10NF3OXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELyN2RKSzVyPUiuNFM{QTVizszNNUXFe3lxW0GQR1XS
EW-16NWTZVVhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRThwMEi0OFUh|ryPMoXlV2FPT0WU
DOHH-2NE\GdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLpTWM2OD16LkKwNFk2KM7:TR?=MWHTRW5ITVJ?
NCI-H1581MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rEVmlEPTB;OD6yOlMzOyEQvF2=NFfwWoFUSU6JRWK=
TE-5NVfz[XJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRThwNEK0Nlkh|ryPNW\aOFV{W0GQR1XS
CAKI-1M{W2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRThwNUeyNlIh|ryPNHPXeXhUSU6JRWK=
A673NYTwXXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPNUGhKSzVyPUiuOlMzODJizszNM2L0VXNCVkeHUh?=
CAL-12TM1HydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnG4TWM2OD16Lk[1O|U{KM7:TR?=NFXKW5hUSU6JRWK=
DBTRG-05MGNFjUcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfo[2NXUUN3ME24Mlc1QDV7IN88US=>M4S1RXNCVkeHUh?=
SK-N-FIMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1v2U2lEPTB;OD64NVM4QSEQvF2=M2Czb3NCVkeHUh?=
K-562NF\WfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRThwOEO5OVch|ryPM1POZnNCVkeHUh?=
SBC-1MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfFVIY2UUN3ME24Mlg3PjR3IN88US=>NWTRWIVUW0GQR1XS
ES4Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRThwOE[4PFQh|ryPM3TRSXNCVkeHUh?=
MS-1NFv0WnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRThwOEe1NVch|ryPMmrKV2FPT0WU
RKONE\j[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zHUmlEPTB;OD64PVA2PyEQvF2=NYPOTG45W0GQR1XS
NCI-H1693NVn5VWNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLkTWM2OD16LkmyNVch|ryPNXzxdmNSW0GQR1XS
SW954NWrDOHJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlruTWM2OD16Lkm2PVc5KM7:TR?=NI[xd4tUSU6JRWK=
SK-UT-1MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7pXJBvUUN3ME24Mlk4Pjh|IN88US=>NYXw[4dQW0GQR1XS
T98GM{\Wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGW5OHVKSzVyPUiuPVk5PDZizszNM4K1UHNCVkeHUh?=
NCI-H2126M3\qeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTlwMEC4NlYh|ryPM1PVVnNCVkeHUh?=
TE-12NI[3S5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DVeGlEPTB;OT6wN|M3PyEQvF2=NIrLZ5FUSU6JRWK=
DK-MGNVHOd2xyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWL3dHNYUUN3ME25MlIyOTlzIN88US=>MUDTRW5ITVJ?
MEG-01NVrRb3BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4G2d2lEPTB;OT6yOFk{OSEQvF2=MmHaV2FPT0WU
HCC1937MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXnOHBSUUN3ME25MlI6ODlzIN88US=>M4rqZXNCVkeHUh?=
MKN45NUHDZW12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLjTWM2OD17LkS1NFY2KM7:TR?=MXXTRW5ITVJ?
NCI-H1792M3XvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTlwNEWyNVkh|ryPM1nxWnNCVkeHUh?=
SW1417MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUflN5llUUN3ME25MlU3QDN5IN88US=>NEHaXodUSU6JRWK=
639-VNGnRc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXL3N|JLUUN3ME25MlY1Ozh6IN88US=>MVXTRW5ITVJ?
P30-OHKNUPMXHZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTlwNkWzNVYh|ryPNWTsfoRPW0GQR1XS
YKG-1NUO4ZY1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rXPGlEPTB;OT63OVA{OyEQvF2=NXWxZ5VsW0GQR1XS
KGNNWDRdIV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHCTWM2OD17LkizO|k2KM7:TR?=MVrTRW5ITVJ?
MSTO-211HNFz5WZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmntTWM2OD17Lkm1OVI6KM7:TR?=M2roZXNCVkeHUh?=
NCI-H1573NF\zXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH32VZRKSzVyPUGwMlE2PzRizszNNWnHOm8xW0GQR1XS
NCI-H720MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTFyLkG5PFkh|ryPM2O0[3NCVkeHUh?=
KARPAS-45NFvlV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTFyLkK3PVUh|ryPMWjTRW5ITVJ?
MDA-MB-175-VIIMnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nCdGlEPTB;MUCuOFgh|ryPMkGxV2FPT0WU
SK-NEP-1NWTUbYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPXTWM2OD1zMD60PVgyKM7:TR?=M2\DZXNCVkeHUh?=
MKN28Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIL3O2dKSzVyPUGwMlUyQCEQvF2=NHu5R|hUSU6JRWK=
KYSE-520M4G5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;6ZWlEPTB;MUCuOVIh|ryPNEmzXplUSU6JRWK=
KE-37NIDVU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTwUJVKSzVyPUGwMlUzPzJizszNMXvTRW5ITVJ?
VA-ES-BJNIe4[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrYN|ZKSzVyPUGwMlU3PyEQvF2=NFvwSYJUSU6JRWK=
CCRF-CEMM{nUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37MOGlEPTB;MUCuOVY5PCEQvF2=MYfTRW5ITVJ?
GMS-10Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTFyLk[wPVQh|ryPM{TVVXNCVkeHUh?=
NCI-H1623MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTFyLk[zO|kh|ryPNIXwO5lUSU6JRWK=
NEC8MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LuVmlEPTB;MUCuO|c4OyEQvF2=MUnTRW5ITVJ?
MOLT-16NWqzU2liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2qwRWlEPTB;MUCuPFEyOyEQvF2=NEPlelhUSU6JRWK=
DJM-1M13Mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHFdZlKSzVyPUGxMlA{PzlizszNNWPhW2xjW0GQR1XS
U251M4DXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTFzLkC0NkDPxE1?M37GPHNCVkeHUh?=
SBC-5NVXOdlFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\GRWlEPTB;MUGuNVQ3PyEQvF2=MUPTRW5ITVJ?
SW756MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;BRYxKSzVyPUGxMlIyPTRizszNM{HYN3NCVkeHUh?=
KS-1NWfaRo8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoT6TWM2OD1zMT6yOlE6KM7:TR?=M{XOWHNCVkeHUh?=
SF295M1XhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGW2PWtKSzVyPUGxMlMyODRizszNM{ThWHNCVkeHUh?=
YH-13MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvuOG5ZUUN3ME2xNU4{OjZ5IN88US=>NFXGTVZUSU6JRWK=
SW837NH\rUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYH0UYlnUUN3ME2xNU4{PTB4IN88US=>NE\w[XdUSU6JRWK=
KYSE-450MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrjZ4JKSzVyPUGxMlQxPTdizszNMlPLV2FPT0WU
KYSE-180NXuwTHNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\PU2lEPTB;MUGuOFgzKM7:TR?=MnTTV2FPT0WU
S-117MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7HTWM2OD1zMT60PFk3KM7:TR?=NVTNTmdHW0GQR1XS
KOSC-2MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVO0VZBXUUN3ME2xNU43OjJ{IN88US=>NUfrTm55W0GQR1XS
KYSE-270NUfNT2FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTFzLki3OFUh|ryPMnnFV2FPT0WU
D-336MGNWDzNGhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTFzLkmwO|Uh|ryPM{PoXHNCVkeHUh?=
KALS-1NXHyPHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3H1NmlEPTB;MUKuNFAyPiEQvF2=M{HtcXNCVkeHUh?=
LB373-MEL-DMnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPicIEzUUN3ME2xNk4xPTN|IN88US=>M4\pR3NCVkeHUh?=
HLEM1fpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvabmdMUUN3ME2xNk4xPTh3IN88US=>NGWxPXVUSU6JRWK=
SJSA-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPWZmFKSzVyPUGyMlA4OzVizszNM4DENHNCVkeHUh?=
SW1990MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHEc49KSzVyPUGyMlA6OTFizszNNX7jdo1YW0GQR1XS
NOS-1M{LWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\4VHpMUUN3ME2xNk4yOzV{IN88US=>NWSyZXNFW0GQR1XS
GI-ME-NMln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1qyPGlEPTB;MUKuNlE3OyEQvF2=NWHUSXB1W0GQR1XS
NCI-H1703MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTF{LkK2NVYh|ryPM4jnPHNCVkeHUh?=
ES7NV7IcJpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTXOZd4UUN3ME2xNk4zPzJ2IN88US=>NIHjTphUSU6JRWK=
KYSE-510MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jQWWlEPTB;MUKuOVA4QSEQvF2=M2jSVnNCVkeHUh?=
BHYNFnEPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4n3PGlEPTB;MUKuOVMxPyEQvF2=M4X0RnNCVkeHUh?=
TCCSUPNH7BRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELp[ndKSzVyPUGyMlU4PTdizszNMoXoV2FPT0WU
HSC-2M4PqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPwTWM2OD1zMj61PVk3KM7:TR?=NHXuVFNUSU6JRWK=
BENNHvVXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTF{Lk[xOFMh|ryPMXfTRW5ITVJ?
769-PMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vjV2lEPTB;MUKuO|kzPCEQvF2=NULJU2RQW0GQR1XS
HTM3naN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfSUINpUUN3ME2xNk45OzR4IN88US=>MV\TRW5ITVJ?
LXF-289M3m4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\CRWlEPTB;MUKuPVU{OSEQvF2=MWDTRW5ITVJ?
OVCAR-3M{W4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELXNWFKSzVyPUGyMlk2PjdizszNMmjEV2FPT0WU
ATN-1NEez[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLSTWM2OD1zMz6wNVg1KM7:TR?=NVLP[28{W0GQR1XS
8-MG-BANWfBTVY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTF|LkC0OVUh|ryPNEPWdXFUSU6JRWK=
SW13NGXMbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFWxcG1KSzVyPUGzMlEyPjVizszNM4fyVnNCVkeHUh?=
NCI-H1092NV;EcGdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTF|LkG2NkDPxE1?NHXTUJpUSU6JRWK=
OAW-42MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jMPGlEPTB;MUOuNVk{PyEQvF2=M1;ZVnNCVkeHUh?=
NCI-H2452NIPDPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nrWGlEPTB;MUOuNlE4PSEQvF2=NYHBdFNvW0GQR1XS
CAPAN-1NWnTe25LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjCTWJrUUN3ME2xN{42PTF2IN88US=>MoDJV2FPT0WU
NCI-H2009M2PHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLKTWM2OD1zMz61PVE6KM7:TR?=NXHxSJpIW0GQR1XS
SF268M{PrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPpOXBTUUN3ME2xN{43OzJ4IN88US=>MoTKV2FPT0WU
GCIYNWnzeJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlW3TWM2OD1zMz62PVI4KM7:TR?=M2XYN3NCVkeHUh?=
OS-RC-2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF|Lkm1NFEh|ryPMl;FV2FPT0WU
GCTNHTjS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHwTWM2OD1zMz65Olk4KM7:TR?=NVraOnpVW0GQR1XS
NB17NUDqdIozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jBfGlEPTB;MUSuNFg2KM7:TR?=M{ftRXNCVkeHUh?=
NCI-H2030NHHmOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\KTWM2OD1zND6xOFY2KM7:TR?=NVjl[ZVXW0GQR1XS
HC-1NFjoW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33uSGlEPTB;MUSuNlA5PyEQvF2=NXHwbW1xW0GQR1XS
QIMR-WILMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTF2LkO0NVIh|ryPM1LwU3NCVkeHUh?=
Capan-2MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPuTWM2OD1zND6zO|E1KM7:TR?=M1TDXXNCVkeHUh?=
BALL-1M2i4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXT[lhEUUN3ME2xOE41PjZ3IN88US=>NHjaenNUSU6JRWK=
LS-1034M{PtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTF2Lk[xOVIh|ryPNXy1bJozW0GQR1XS
U-118-MGMorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnKZWtKSzVyPUG0MlY{OSEQvF2=NWnvNFQyW0GQR1XS
NCI-H630NFL2XHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzteIxEUUN3ME2xOE43PTZ6IN88US=>M17aTHNCVkeHUh?=
OVCAR-8NHT2VJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Xa[WlEPTB;MUSuO|IxOSEQvF2=NH:yTpJUSU6JRWK=
NCI-H2347MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nNZ2lEPTB;MUSuPFI{KM7:TR?=MorqV2FPT0WU
BT-549NXXk[Hp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4qzbWlEPTB;MUSuPFI5PCEQvF2=NIfFV|dUSU6JRWK=
LB831-BLCMn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfDXGNKSzVyPUG0Mlg6OzRizszNNIT5ZndUSU6JRWK=
NCI-H661NIXKe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXsTWM2OD1zND65OVkh|ryPNVHUe4xLW0GQR1XS
MKN7MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTF3LkCwPVMh|ryPNICwfpJUSU6JRWK=
U-87-MGM2TzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF2wfo1KSzVyPUG1MlA5QTdizszNMX7TRW5ITVJ?
OVCAR-4NW\Uc4NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TEVmlEPTB;MUWuNVQzPCEQvF2=MonVV2FPT0WU
OE33Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTRTWM2OD1zNT6xO|EyKM7:TR?=NVrJ[4JGW0GQR1XS
EC-GI-10NXfYU5pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTF3LkKzOVch|ryPMn\6V2FPT0WU
AM-38NHnzVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm[zTWM2OD1zNT6yO|E4KM7:TR?=M{G1SHNCVkeHUh?=
NCI-H1563NYXPXW1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHsTWM2OD1zNT6zOFkh|ryPM1vhZ3NCVkeHUh?=
SCC-4MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrVTWM2OD1zNT60NVA{KM7:TR?=NHLqOVBUSU6JRWK=
Detroit562MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPGdmlKSzVyPUG1MlQ2PDdizszNNU\jblhCW0GQR1XS
PC-14NI\hSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXeyN2p[UUN3ME2xOU41QDZ4IN88US=>MVLTRW5ITVJ?
ES3MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLpTWM2OD1zNT61N|Yh|ryPMo\3V2FPT0WU
OCI-AML2MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LofWlEPTB;MUWuO|YyPCEQvF2=NWrQcW94W0GQR1XS
LU-134-ANIfUfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrFNWZKSzVyPUG1MlkxOThizszNNUHweY96W0GQR1XS
SASNWC5UZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXsTWM2OD1zNT65N|c{KM7:TR?=MkXPV2FPT0WU
TGBC11TKBNGPpcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTF3Lkm0NVQh|ryPMoqyV2FPT0WU
HOP-62M2rvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\Z[YxKSzVyPUG1Mlk2QTdizszNNVX6SWoyW0GQR1XS
G-401MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTNTWM2OD1zNT65OlQ6KM7:TR?=MljuV2FPT0WU
NCI-H28M17NNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTF4LkC4OVYh|ryPNWXlRXVmW0GQR1XS
A204M3nLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPUToRKSzVyPUG2MlIxODZizszNM{LRNXNCVkeHUh?=
NCI-H1299NXnuS2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml[3TWM2OD1zNj6yNlkyKM7:TR?=M4f3S3NCVkeHUh?=
VMRC-RCZNYrBPHR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzhU2lKSzVyPUG2MlI2QTJizszNNV7Tb3k6W0GQR1XS
BxPC-3MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIO2VIhKSzVyPUG2MlI5PTZizszNM{TDVXNCVkeHUh?=
NCI-H2228M3LH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MomwTWM2OD1zNj61NVU5KM7:TR?=MYTTRW5ITVJ?
NCI-H23NUHYS3B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH24SpFKSzVyPUG2MlYxPzhizszNNHXTWpJUSU6JRWK=
NKM-1NFHrO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TLSGlEPTB;MUeuNFE5QSEQvF2=NFjQXYlUSU6JRWK=
KYSE-70MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfJTIx[UUN3ME2xO{4zQDlizszNM{nrc3NCVkeHUh?=
BB49-HNCNWjqXmgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTF5LkW2PFYh|ryPM2e5VXNCVkeHUh?=
SCC-15MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPPR|hKSzVyPUG3Mlg1PzNizszNNVL1VnY1W0GQR1XS
D-247MGMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\hOGlEPTB;MUeuPVI1PyEQvF2=NXHX[FNsW0GQR1XS
BB30-HNCM1zLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF:2WWpKSzVyPUG4MlA{OThizszNM2LROXNCVkeHUh?=
CAL-85-1MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PlVmlEPTB;MUiuNVgxQSEQvF2=NFPyVFZUSU6JRWK=
HT-3MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnH5TWM2OD1zOD6zPVc4KM7:TR?=NFf3PVJUSU6JRWK=
KYSE-410M1\kcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PwV2lEPTB;MUiuOFU4PyEQvF2=NHqxNYhUSU6JRWK=
SW982M{O2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrXWmdKSzVyPUG4MlU3PDlizszNMUHTRW5ITVJ?
SW962NHPxfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3HfZkxUUN3ME2xPE42PzB{IN88US=>MXLTRW5ITVJ?
Ramos-2G6-4C10MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEOzSmpKSzVyPUG4MlU6OjdizszNM4jqSnNCVkeHUh?=
OC-314MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInJc|FKSzVyPUG4Mlc{QDRizszNMoLaV2FPT0WU
LS-123MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3nWZpKSzVyPUG4Mlc6ODFizszNM1TSSXNCVkeHUh?=
D-502MGNHHsT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGS5RYJKSzVyPUG4MlgyOzlizszNMYLTRW5ITVJ?
RO82-W-1NX3KR|RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPuTWM2OD1zOD64Nlg5KM7:TR?=NH7hPZZUSU6JRWK=
HuO9M1naNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTF7LkGzO|kh|ryPM1LySXNCVkeHUh?=
ETK-1NG\INHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;kT2lEPTB;MUmuNVgzPyEQvF2=NVfhfldZW0GQR1XS
SNU-387NYHXWmlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\2TWM2OD1zOT6xPFg6KM7:TR?=M4HYOnNCVkeHUh?=
SW1573MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTF7LkG5Olkh|ryPMnP6V2FPT0WU
NTERA-S-cl-D1M3XnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LnNWlEPTB;MUmuNlAxPyEQvF2=M2XG[XNCVkeHUh?=
SF126NET6V|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTF7LkO1NFIh|ryPM2jxRXNCVkeHUh?=
Calu-3NHOzWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTF7LkSyN|ch|ryPNIPL[HVUSU6JRWK=
NCI-H1048M1y5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTaOo91UUN3ME2yNE4{OjZ4IN88US=>NY\vdVBTW0GQR1XS
NCI-H226NXfRUopJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LBdGlEPTB;MkCuOFM6QSEQvF2=MXPTRW5ITVJ?
FTC-133M3zoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1:yU2lEPTB;MkCuOFcxOyEQvF2=MUfTRW5ITVJ?
SF539MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHETWM2OD1{MD61NVczKM7:TR?=NH3Jc|lUSU6JRWK=
TE-6MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPabG97UUN3ME2yNE45ODZ5IN88US=>NFuzSXFUSU6JRWK=
UMC-11NUTjfoduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjITWM2OD1{MD65NVY1KM7:TR?=NFjG[lZUSU6JRWK=
BeckerNWX4TFhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkW3TWM2OD1{MT6xNVE5KM7:TR?=NVvDPGZwW0GQR1XS
KP-4M4nzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{C5cWlEPTB;MkGuNVE6PiEQvF2=MlL5V2FPT0WU
ChaGo-K-1NWXxeYZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LYV2lEPTB;MkGuN|YzPyEQvF2=MoOwV2FPT0WU
CFPAC-1NFrScFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFj5SHRKSzVyPUKxMlM5PThizszNNFfaSnVUSU6JRWK=
A498MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPvNXFDUUN3ME2yNU42OzF{IN88US=>M1TqcXNCVkeHUh?=
NCI-H1755MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrBSGlKSzVyPUKxMlY4PDFizszNMVTTRW5ITVJ?
TI-73NYPyWHp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTPeHBsUUN3ME2yNk4{OjhizszNNVvvVHRoW0GQR1XS
NCI-H441M{ezfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlS3TWM2OD1{Mj61Olg6KM7:TR?=MU\TRW5ITVJ?
CaR-1NUnBe4hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTMTWM2OD1{Mz6wNlE{KM7:TR?=MXTTRW5ITVJ?
HCC1806NEjpb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33GOmlEPTB;MkOuNFU5OyEQvF2=MVrTRW5ITVJ?
SNU-449MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUmzRos5UUN3ME2yN{4{OjlizszNMnXyV2FPT0WU
EKVXMmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm[2TWM2OD1{Mz6zPVA6KM7:TR?=NYj1ZmdsW0GQR1XS
DMS-114MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\a[IhKSzVyPUKzMlU4PjVizszNNYOzU3RFW0GQR1XS
A704MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF:0c4NKSzVyPUKzMlYyODNizszNMoSyV2FPT0WU
LC-2-adMoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETMSJlKSzVyPUKzMlYyPDdizszNMVzTRW5ITVJ?
VM-CUB-1MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XKVGlEPTB;MkOuO|M1OSEQvF2=NIHCfZNUSU6JRWK=
PC-3NXH4WldNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3y0d2lEPTB;MkSuNFUzPiEQvF2=MVvTRW5ITVJ?
HELMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDV[ZVCUUN3ME2yOE4xQDZ3IN88US=>Mnr0V2FPT0WU
ABC-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3wb2xKSzVyPUK0MlI4OjlizszNM{\OTXNCVkeHUh?=
COLO-680NMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTJ2LkS3OlQh|ryPMUHTRW5ITVJ?
MZ1-PCM{i0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7oTWM2OD1{ND62PFch|ryPMoHhV2FPT0WU
NCI-H69MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\zTWM2OD1{ND63N|U1KM7:TR?=NIHNVpVUSU6JRWK=
TE-1NGn4NItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILvWI1KSzVyPUK1MlA1QTlizszNMYXTRW5ITVJ?
EW-3NHHmVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTJ3LkGxN{DPxE1?MmrIV2FPT0WU
PANC-08-13MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\STWM2OD1{NT64NVA{KM7:TR?=NWfGO2t3W0GQR1XS
NMC-G1MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTJ4LkCwPFgh|ryPMlrIV2FPT0WU
BT-20NF3rRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTS[oVKSzVyPUK2MlQ2PDNizszNMWTTRW5ITVJ?
TGBC24TKBNV;lfmFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTrRXF3UUN3ME2yOk44OzNzIN88US=>MYDTRW5ITVJ?
TE-11MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLJTWM2OD1{Nj65PFk2KM7:TR?=MkTBV2FPT0WU
ESS-1MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjNTWM2OD1{Nz6zNlE3KM7:TR?=MWDTRW5ITVJ?
JVM-3MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGL2THFKSzVyPUK3MlY1PzVizszNM{fUd3NCVkeHUh?=
C3AM4PWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1uxOGlEPTB;MkeuPFQ6PiEQvF2=NVf6boY{W0GQR1XS
MDA-MB-157NYCzZYdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHIfVJYUUN3ME2yO{45PzV|IN88US=>M4qwTXNCVkeHUh?=
KLEMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nUN2lEPTB;MkiuNVA2QCEQvF2=NWTtdFNRW0GQR1XS
ES1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fIfWlEPTB;MkiuNVg{QCEQvF2=NFPPVYZUSU6JRWK=
CAL-120NWD4SpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjCcng{UUN3ME2yPE4{QTl7IN88US=>MofhV2FPT0WU
NCI-N87MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnyWFJKSzVyPUK4MlUyODVizszNM4nYcnNCVkeHUh?=
RPMI-8226M1SwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M174RmlEPTB;MkmuNVg1OyEQvF2=NHz1bXNUSU6JRWK=
COR-L88Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofXTWM2OD1{OT6yOFE6KM7:TR?=NU\YOVRQW0GQR1XS
UACC-893NFm4VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJ7LkOxN|ch|ryPM1e2dXNCVkeHUh?=
C8166MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmf5TWM2OD1{OT65PVk3KM7:TR?=NHL0c3pUSU6JRWK=
J82M1HvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XNR2lEPTB;M{CuPFE1PyEQvF2=NIK0c|ZUSU6JRWK=
PFSK-1MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rPWGlEPTB;M{GuNFY2QSEQvF2=M2\5VXNCVkeHUh?=
COLO-684M4T1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTNzLkSzO|Qh|ryPNXXvWohKW0GQR1XS
CAL-72MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTNzLkW3Nlkh|ryPM3LtPHNCVkeHUh?=
SNB75M17semdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3mzO2lEPTB;M{GuPFk4KM7:TR?=NY\2U2o6W0GQR1XS
MDA-MB-415M{[4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TaRWlEPTB;M{GuPVc3OiEQvF2=M{fLRXNCVkeHUh?=
SiHaNVzk[W54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFH5dJJKSzVyPUOyMlQ4OTFizszNNICxXFFUSU6JRWK=
NCI-H1648M2D2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DEWmlEPTB;M{KuPVM1PSEQvF2=MmT0V2FPT0WU
EFO-21NFz0ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTN|LkCwOUDPxE1?NXrEXWoyW0GQR1XS
HCC38NWrZZWxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzDTWM2OD1|Mz6zPFQyKM7:TR?=NGX4cVFUSU6JRWK=
IA-LMNVzCfmY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3GUHcxUUN3ME2zN{44QDh7IN88US=>MVfTRW5ITVJ?
CTV-1M4O2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGK5TYhKSzVyPUOzMlk4QDZizszNMXLTRW5ITVJ?
NCI-H446M3m1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjRVoZ[UUN3ME2zOE4zPjh7IN88US=>MVjTRW5ITVJ?
IST-SL1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LydmlEPTB;M{SuO|QxQCEQvF2=NGHxXmlUSU6JRWK=
EW-22NH3WeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTN2Lke3OVkh|ryPMlPuV2FPT0WU
JEG-3M1fnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYT2b4hTUUN3ME2zOk4yPzZ4IN88US=>NYfRRWluW0GQR1XS
LU-65NXXwW5BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHFZ4RKSzVyPUO2MlI6QDVizszNMWjTRW5ITVJ?
NCI-H596MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M36wcGlEPTB;M{[uPVU6OSEQvF2=MnfRV2FPT0WU
KNS-81-FDNGTxT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILpVWJKSzVyPUO3MlE1PSEQvF2=NUntfmNHW0GQR1XS
NCI-H1793M{\JPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLWRo5KSzVyPUO3MlcxQDZizszNNXvXTYlSW0GQR1XS
NCI-H460M4HIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jpS2lEPTB;M{iuNFg4OyEQvF2=MkjCV2FPT0WU
MPP-89MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEX0fY5KSzVyPUO5MlU5QDZizszNNIPLZZhUSU6JRWK=
D-542MGM2faWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGL6dndKSzVyPUO5Mlg1OzZizszNM4XGdXNCVkeHUh?=
JARM1zXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFG2SJZKSzVyPUSwMlQ4ODVizszNM3facnNCVkeHUh?=
NCI-H209M2D0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{G1XGlEPTB;NECuOlc4KM7:TR?=NXvWdlc2W0GQR1XS
G-402NEX3eYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDs[HR3UUN3ME20NU4{QTl|IN88US=>NYjE[|drW0GQR1XS
IST-MES1NHvkXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37oPWlEPTB;NEKuNVk{PSEQvF2=M1vqSnNCVkeHUh?=
DaoyMnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\OdWlEPTB;NEKuOVQ4OSEQvF2=M1jCR3NCVkeHUh?=
EW-11MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTR|LkGyNVEh|ryPMmf2V2FPT0WU
Saos-2MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUizRWFtUUN3ME20N{4yPTN5IN88US=>NHTkXXdUSU6JRWK=
no-10M1:5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nh[GlEPTB;NEOuNVcxOiEQvF2=MmrkV2FPT0WU
HCC1395NIPqVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTR|LkS2OFQh|ryPNEnneXRUSU6JRWK=
HCE-4NWnORYhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTR|Lke2OlQh|ryPNX3XOGF4W0GQR1XS
EW-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzmfXBKSzVyPUSzMlgxPDlizszNNXPkcZQ{W0GQR1XS
OCUB-MNUL1dIJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\hTWM2OD12ND6zOlM5KM7:TR?=MUDTRW5ITVJ?
IGR-1M1nFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTR2LkSxNVUh|ryPM4TKfnNCVkeHUh?=
NCI-H1838NFXaU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXrOmRKSzVyPUS0MlQ{PDlizszNM1;jT3NCVkeHUh?=
NCI-H2405Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWntO4pIUUN3ME20OE42OzRizszNMmLXV2FPT0WU
GB-1NUDucXY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnv0TWM2OD12ND63OFY{KM7:TR?=MlyyV2FPT0WU
MG-63MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPjTWM2OD12Nj6wOlk3KM7:TR?=M{jJZXNCVkeHUh?=
KP-N-YNNGjmWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIq2RW5KSzVyPUS2MlQ3PzlizszNMmfOV2FPT0WU
no-11MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTR5LkCyOFQh|ryPNYj3XIFLW0GQR1XS
SW948M4fNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXPcnhHUUN3ME20O{4{Ozd5IN88US=>NUDWN4FPW0GQR1XS
CAMA-1NIrIXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nsXWlEPTB;NEeuN|Q{QCEQvF2=NH3jfppUSU6JRWK=
HCC1187NFXEdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTR5LkWxJO69VQ>?M1WyWXNCVkeHUh?=
D-392MGNEXTWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PBe2lEPTB;NEeuOlUyPiEQvF2=NV6wVndFW0GQR1XS
647-VMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPJTWM2OD12OT6zOFE1KM7:TR?=NX3hSmN2W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]
Features First MEK inhibitor to begin clinical development.

Protocol(Only for Reference)

Kinase Assay:

[2]

MEK1 Assay MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.

Cell Assay:

[1]

Cell lines Colon 26 carcinoma cells
Concentrations 0.1-10 μM
Incubation Time 24 hours
Method

Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.

Animal Study:

[3]

Animal Models PTC cells in athymic mice
Formulation Cremophor EL–95% ethanol (50:50) and dilutes with water
Dosages 150 mg/kg
Administration Orally twice daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Sebolt-Leopold JS, et al. Nat Med, 1999, 5(7), 810-816.

[2] Davies SP, et al. Biochem J, 2000, 135(1), 95-105.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-18)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Insti  ...more University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Chemical Information

Download PD184352 (CI-1040) SDF
Molecular Weight (MW) 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide

Customer Product Validation(12)


Click to enlarge
Rating
Source Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck
Method Immunohistochemistry
Cell Lines Hand2d/d mice
Concentrations
Incubation Time 24h
Results The epithelia of vehicle-treated horn showed prominent expression of p-FRS2 and p-ERK1/2(Fig.A,a and c). However, the levels of both p -FRS2 and p -ERK1/2 were reduced in the epithelia of PD173074-treated horn on day 4 of pregnancy (Fig. A, b and d). We also observed a marked decline in the proliferative activity of Hand2-null uterine epithelia, as indicated by decreased Ki-67 staining (Fig. A, e and f) . In parallel experiments, administration of PD184352, an inhibitor of the ERK1/2 pathway, to uterine horns of Hand2 d/d mice suppressed the level of pERK1/2 (Fig.B, a and b) , as well as luminal epithelial proliferation ( Fig. B, c and d).The ERK1/2-dependent phosphorylation of epithelial ERα at Ser118 is critical for the transcriptional activation of ERα. Administration of either PD173074 (Fig. C, a to d) or PD184352 (Fig. C, e to h) to Hand2-null uterine horns blocked the phosphorylation of epithelial ERα at Ser118 and the expression of Muc -1.

Click to enlarge
Rating
Source J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck
Method Western Blot
Cell Lines primary human melanocytes
Concentrations 1 uM
Incubation Time 18 h
Results In BRAFV600E melanoma cells, the highly selective BRAFV600E inhibitor GDC-0879 and three selective MEK inhibitors [PD184352/CI-1040, U0126, PD98059] did not suppress c-Jun levels, although they effectively reduced phospho-ERK levels.

Click to enlarge
Rating
Source J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck
Method Xenograft
Cell Lines athymic nude Foxn1nu mice
Concentrations 3 mg/kg
Incubation Time 13 day
Results CDK2/4 inhibition augmented statistically significant growth reduction of melanoma xenografts in vivo by the BRAF and MEK inhibitors (GDC-0879 and CI1040).

Click to enlarge
Rating
Source Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck
Method Western blot
Cell Lines DU145/PC3 cells
Concentrations 10 μM
Incubation Time 12 h
Results PI3K inhibition by LY294002 in-creased ERK activation in Her2-overexpressing DU145 cells, whereas treatment with the MEK inhibitor PD184352 in PC3 cells with Her2 overexpression resulted in increased AKT activation. This suggests a strong reciprocal feedback regulation of the PI3K/AKT and MEK/ERK signaling cascades (Fig. E)

Click to enlarge
Rating
Source Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck
Method MTT assay
Cell Lines MDA-MB-453 cell line, HCC-1954 cell line
Concentrations 2-25 μM
Incubation Time 48 h
Results We observed that monotherapies with CI-1040 and other inhibitors reduced cell viability in a dose-dependent manner across these cell lines

Click to enlarge
Rating
Source Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck
Method MTT assay/Western blot
Cell Lines MDA-MB-453-R cell line
Concentrations 5/10 μM
Incubation Time 48 h
Results "Flutamide and CI-1040 treatments were carried out at the same four dose combinations applied before in the nonresistant line (CI-1040(5μM)/flutamide(5μM), CI-1040 (10μM) /flutamide (5μM), CI-1040 (5μM)/flutamide (10μM), and CI-1040(10 μM)/f lutamide (10μM)). Importantly, we observed a synergy at all four dose combinations in MDA -MB-453-R line with CI values of 0.68 to 0.76 (Figure D). Combination therapies with CI-1040 (5μM)/f lutamide (5μM) and CI-1040 (5μM)/flutamide (10μM) completely abrogated ERK phosphorylationin MDA-MB-453-R line (Figure F).

Click to enlarge
Rating
Source Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck
Method Western blot
Cell Lines MDA-MB-453 cell lines, HCC-1954 cell lines
Concentrations 10 μM
Incubation Time 24 h
Results We observed that CI-1040 at 10μM concentration almost completely inhibited ERK phosphorylation in both cell lines

Click to enlarge
Rating
Source Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck
Method RT-PCR
Cell Lines MDA-MB-453 cell lines, HCC-1954 cell lines
Concentrations 10 μM
Incubation Time 24 h
Results We assessed AR expression using RT-PCR and observed a significant reduction of AR transcript level after MEK inhibition by CI-1040 to 0.2- and 0.6-fold in MDA-MB- 453 and HCC-1954 cells, respectively, compared with the controls (P < .01; Figure A). This finding suggest that ERK signaling regulates AR expression in molecular apocrine cells.

Click to enlarge
Rating
Source Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck
Method MTT assay
Cell Lines MDA-MB-453 cell line, HCC-1954 cell line, HCC-202 cell line
Concentrations 5/10 μM
Incubation Time 48 h
Results These data suggest that AR inhibitor flutamide and MEK inhibit or CI-1040 have synergy in reducing cell viability of molecular apocrine cell lines.

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source 2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 3 h
Results

Click to enlarge
Rating
Source 2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck
Method Cell colony formation assays
Cell Lines primary hematopoietic cells
Concentrations 10 μM
Incubation Time
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related MEK Products

  • Cobimetinib (GDC-0973, RG7420)

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.

  • BI-847325

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

  • GDC-0623

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • Binimetinib (MEK162, ARRY-162, ARRY-438162)

    Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

  • Refametinib (RDEA119, Bay 86-9766)

    Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Recently Viewed Items

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us